292 reports of this reaction
3.5% of all SAPROPTERIN DIHYDROCHLORIDE reports
#5 most reported adverse reaction
MATERNAL EXPOSURE DURING PREGNANCY is the #5 most commonly reported adverse reaction for SAPROPTERIN DIHYDROCHLORIDE, manufactured by BioMarin Pharmaceutical Inc.. There are 292 FDA adverse event reports linking SAPROPTERIN DIHYDROCHLORIDE to MATERNAL EXPOSURE DURING PREGNANCY. This represents approximately 3.5% of all 8,360 adverse event reports for this drug.
Patients taking SAPROPTERIN DIHYDROCHLORIDE who experience maternal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MATERNAL EXPOSURE DURING PREGNANCY is moderately reported among SAPROPTERIN DIHYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to maternal exposure during pregnancy, the following adverse reactions have been reported for SAPROPTERIN DIHYDROCHLORIDE:
The following drugs have also been linked to maternal exposure during pregnancy in FDA adverse event reports:
MATERNAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 292 FDA reports for SAPROPTERIN DIHYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MATERNAL EXPOSURE DURING PREGNANCY accounts for approximately 3.5% of all adverse event reports for SAPROPTERIN DIHYDROCHLORIDE, making it a notable side effect.
If you experience maternal exposure during pregnancy while taking SAPROPTERIN DIHYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.